Please login to the form below
Advent
This page shows the latest Advent news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca blocks take-private buyout of Sobi
The $7.6bn takeover of Swedish rare disease company Sobi by private equity group Advent International and Singapore’s wealth fund failed to convince the 90% of shareholders needed. ... The Board supported the public offer by Advent and GIC as we
Latest news
-
UK immunology biotech MiroBio launches with $34m fundraising
MiroBio’s Series A financing was co-led by Oxford Sciences Innovation and Samsara Biocapital, with Advent Life Sciences and SR One also joining the round. ... For the time being MiroBio has four directors – one apiece from each of its backers –
-
Hudson named Brandicourt’s successor as Sanofi’s CEO
deal and selling off its European generics business to private equity group Advent for $2.4bn, whilst implementing a big cost-reduction programme.
-
Gottlieb admonishes industry for clinical trial failings
Gottlieb – who is leaving the FDA next month and will be replaced on an interim basis by National Cancer Institute (NCI) director Ned Sharpless – says that the advent in precision medicine,
-
Pfizer’s flat sales focus investor attention on M&A
In the last few weeks Sanofi has sold its European generics business to Advent, GlaxoSmithKline divested its rare disease unit to start-up Orchard Therapeutics after buying Novartis out of a
-
P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit
In the last few weeks Sanofi has sold its European generics business to Advent, GlaxoSmithKline divested its rare disease unit to start-up Orchard Therapeutics after buying Novartis out of a
More from news
Approximately 3 fully matching, plus 95 partially matching documents found.
Latest Intelligence
-
Charting patient pathways with precision for better healthcare
He sees the advent of integrated care systems in the NHS adding extra potency to mapping patient pathways and wants it underpinned by investment focused more on preventative measures to move
-
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
Vikki Ward, European Project and Content Delivery Lead at Havas Lynx Group, believes the advent of virtual and hybrid events is democratising health education by making it easier to spread scientific
-
Follow the user – democratising medical conference design
webinar. With the advent of a highly contagious virus, priorities changed and the wish to avoid infection became as strong as the need to learn about the virus’s implications for
-
Three ways AI will change healthcare in the next decade
format. The advent of natural speech means that doctors will even be able to ask the AI questions verbally and receive accurate responses as though they were seeking help from a
-
Successful product commercialisation: what can we learn from the rare disease setting?
This trend is not surprising – in part driven by the pressures facing healthcare budgets through the rising incidence of chronic diseases, as well as the advent of cell and gene therapies
More from intelligence
Approximately 0 fully matching, plus 40 partially matching documents found.
Latest from PMHub
-
The power of influence in transforming women’s health
This provided an opportunity for natural remedies and non-pharmacological approaches. However, the lack of evidence and the advent of stricter legislation on claims limited their impact.
-
NAVIGATING 2022: THE FIVE CRITICAL SHIFTS PHARMA NEEDS TO EMBRACE
3. The shift to neighbourhood and place-based planning. With the advent of provider collaboratives and primary care networks working within ICSs, we are seeing the gradual dissolution of the boundaries
-
As HCPs Increasingly Expect Personalized Engagement, Pharmas Turn to Modular Intelligent Content. How Does This Work?
While personalized omnichannel communication is becoming the only truly acceptable option in brand communications, Life Sciences are deeply affected by the change. Compared to retail, the amounts of information to deliver alongside the key message
-
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
During the last two decades, the landscape for psoriasis treatment has exploded. The advent of biologic therapies at the turn of the millennium and the subsequent development of T-cell
-
Out Of Office: The New Normal for Ad Agencies
The advent of online approval and asset management. The decline of the salesforce.
More from PMHub
Approximately 0 fully matching, plus 21 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- A new era for UK-Japanese scientific research relations
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- Sanofi Global Health unveils new nonprofit Impact brand
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- A creative awakening – how pharma is bringing innovation to the patient journey
- Behaviour change – a maze of decisions influenced by personal habits, experiences and intentions
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Delivering content to fuel omnichannel engagement
PMHub
Health Unlimited
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
